etoposide + doxorubicin + streptozocin

A **combination chemotherapy regimen** consisting of three cytotoxic agents: etoposide, doxorubicin, and streptozocin. This combination has been used in clinical oncology primarily for the treatment of some advanced neuroendocrine tumors and has been studied in rare tumor types. Each component drug acts via a **distinct mechanism of action** to inhibit cancer cell growth: - **Etoposide** is a topoisomerase II inhibitor that induces DNA strand breaks leading to apoptosis. - **Doxorubicin** is an anthracycline that intercalates into DNA and inhibits topoisomerase II, resulting in disruption of DNA replication and generation of free radicals. - **Streptozocin** is a nitrosourea with DNA alkylating activity, especially used for neuroendocrine tumors due to its relative pancreatic specificity. The regimen has been explored mainly for metastatic or advanced neuroendocrine tumors, such as certain pancreatic and medullary thyroid carcinomas. Toxicities are primarily hematologic, gastrointestinal, and, in the case of doxorubicin, potential cardiac toxicity[1][4].